COVID-19 Prevention and Management: HIV Coinfection, Outpatient Management, Hospitalization, and Post-COVID-19 Complications

COVID-19 Prevention and Management: HIV Coinfection, Outpatient Management, Hospitalization, and Post-COVID-19 Complications

Registration Details

  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Wednesday, July 20, 2022
  • Virtual Fellows: $25.00 (USD)
  • Virtual Fellows ends: Wednesday, July 20, 2022


Constance A. Benson, MD
University of California San Diego
Peter Chin-Hong, MD
University of California San Francisco
Teresa Evering, MD, MS
Weill Cornell Medicine
Rajesh T. Gandhi, MD
Harvard Medical School
Rachel Bender Ignacio, MD, MPH
University of Washington
Arthur Y. Kim, MD
Harvard Medical School


Kara W. Chew, MD, MS
University of California Los Angeles
Ghady Haidar, MD
University of Pittsburgh and UPMC
Jonathan Li, MD, MMSc
Harvard Medical School
Laura Riley, MD
Weill Cornell Medicine

July 20, 2022

8:00 AM - 1:00 PM PT


Last Modified: Sep 15, 2022 @ 3:50 PM

Program Description

This course will be a half-day virtual update covering the latest clinical updates on COVID-19.

This course will include an overview of the clinical relationship between HIV and COVID-19, 2 case-based panel discussions on difficult cases in prevention, outpatient care, and inpatient care for COVID-19, including what drugs to use and when, and a discussion on post-COVID-19 complications, including our current understanding of the mechanisms of long-COVID-19.

Assessment of Needs

Rapid advances in HIV and COVID-19 requires the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management COVID-19 in different clinical settings. Information will be presented through a mix of didactic lectures, clinically relevant cases, and a roundtable discussion developed and led by an expert faculty of HIV/AIDS and COVID-19 clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Describe the potential interaction between COVID-19 and HIV
  • Describe current and investigational therapeutics for the prevention and treatment of acute COVID-19
  • Describe the current best understanding of the long-term complications of COVID-19

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection or COVID-19 and:

  • Provide comprehensive or specialty care for patients with HIV infection
  • Provide outpatient or inpatient care for patients with COVID-19
  • Are currently active in HIV or COVID-19 research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 4.5 hours of continuing nursing education.

This activity is also approved for 4.5 hours of Pharmacotherapy credits.

Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 4.5 contact hours (0.45 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-22-338-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Janssen Therapeutics


Theratechnologies, Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.